$ARQT

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressreleaseex991q22026.htm EX-99.1 Document Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% ve

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. arqt-20260715 FALSE 0001787306 0001787306 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d)

Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.

Arcutis Biotherapeutics (ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for infants with mild to moderate atopic dermatitis aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027, supported by INTEGUMENT-INFANT Phase 2 and Phase 1 PK data. ARQT shares closed at $27.67.

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

Arcutis Biotherapeutics (Nasdaq: ARQT) said it granted 61,000 restricted stock units to 9 newly hired employees under its 2022 Inducement Plan, approved by the Compensation Committee. The RSUs were granted July 1, 2026 and vest over four years (25% annually) if employment continues, per Nasdaq Rule 5635(c)(4).

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. arqt-20260605 FALSE 0001787306 0001787306 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d)

Arcutis Biotherapeutics (ARQT) officer Patrick Burnett sold 222 shares of common stock at $21.05 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units. After the transaction, Burnett directly owns 120,244 shares, indicating the sale was a compensation-related tax event and not a discretionary reduction in his investment.

Arcutis Biotherapeutics, Inc. (ARQT) CFO Latha Vairavan sold 435 shares of common stock at $21.05 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Ms. Vairavan directly holds 85,978 common shares. This sale is a routine tax-related event and not a discretionary market trade.

Arcutis Biotherapeutics, Inc. announced it will report its first quarter 2026 financial results and provide a business update on May 6, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast the same day at 4:30 PM ET, with a replay available on its investor website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a growing portfolio for inflammatory skin diseases.